prikaz prve stranice dokumenta Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study
  Preuzmi
PDF 148.43 KB
Znanstveni rad - Izvorni znanstveni rad
Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study
Dermatology Reports, 11 (2019), 1; 7965. https://doi.org/10.4081/dr.2019.7965
Dehpouri, Tannaz; Rahmatpour Rokni, Ghasem; Ahangar Narenjbon, Nematollah; Goldust, Mohamad; Yamauchi, Paul S.; Wollina, Uwe; Lotti, Torello; Kircik, Leon; Di Lernia, Vito Giuseppe; Sonthalia, Sidharth; Vojvodic, Aleksandra; Szepietowski, Jacek; Bahadoran, Philippe; Errichetti, Enzo; Cantisani, Carmen; Atzori, Laura; Rezaee, Elham; Kutlubay, Zekayi; Engin, Burhan; Nisticò, Steven; Damiani, Giovanni; Conic, Rosalynn R.Z.; Goren, Andy; Čabrijan, Leo; Tchernev, Georgi Više autora...

Citirajte ovaj rad

Dehpouri, T., Rahmatpour Rokni, G., Ahangar Narenjbon, N., Goldust, M., Yamauchi, P. S., Wollina, U. ... Tchernev, G. (2019). Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatology Reports, 11. (1). doi: 10.4081/dr.2019.7965

Dehpouri, Tannaz, et al. "Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study." Dermatology Reports, vol. 11, br. 1, 2019. https://doi.org/10.4081/dr.2019.7965

Dehpouri, Tannaz, Ghasem Rahmatpour Rokni, Nematollah Ahangar Narenjbon, Mohamad Goldust, Paul S. Yamauchi, Uwe Wollina, Torello Lotti, et al. "Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study." Dermatology Reports 11, br. 1 (2019). https://doi.org/10.4081/dr.2019.7965

Dehpouri, T., et al. (2019) 'Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study', Dermatology Reports, 11(1). doi: 10.4081/dr.2019.7965

Dehpouri T, Rahmatpour Rokni G, Ahangar Narenjbon N, Goldust M, Yamauchi PS, Wollina U, i sur.. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatology Reports [Internet]. 09.05.2019. [pristupljeno 05.12.2024.];11(1). doi: 10.4081/dr.2019.7965

T. Dehpouri, et al., "Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study", Dermatology Reports, vol. 11, br. 1, Svibanj 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:654504. [Citirano: 05.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:654504
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study
AutorTannaz Dehpouri
AutorGhasem Rahmatpour Rokni
AutorNematollah Ahangar Narenjbon
AutorMohamad Goldust
AutorPaul S. Yamauchi
AutorUwe Wollina
AutorTorello Lotti
AutorLeon Kircik
AutorVito Giuseppe Di Lernia
AutorSidharth Sonthalia
AutorAleksandra Vojvodic
AutorJacek Szepietowski
AutorPhilippe Bahadoran
AutorEnzo Errichetti
AutorCarmen Cantisani
AutorLaura Atzori
AutorElham Rezaee
AutorZekayi Kutlubay
AutorBurhan Engin
AutorSteven Nisticò
AutorGiovanni Damiani
AutorRosalynn R.Z. Conic
AutorAndy Goren
AutorLeo Čabrijan
AutorGeorgi Tchernev
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za dermatovenerologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Dermatovenerologija
Sažetak (engleski)
Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaDermatology Reports
Brojčani podacivol. 11, br. 1, 7965
p-ISSN2036-7392
e-ISSN2036-7406
DOIhttps://doi.org/10.4081/dr.2019.7965
URN:NBNurn:nbn:hr:184:654504
Datum objave publikacije2019-05-09
URL dokumentahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547029/pdf/dr-11-1-7965.pdf
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2022-02-21 08:47:30